Advertisement
Advertisement
BIIB
Biogen Inc. Common Stock
253.01
USDSponsored
+4.08
+1.64%
Nov 04, 14:37 UTC -5
Open
Biogen Inc. Common Stock (BIIB) Earnings
BIIB Earnings Reports
Positive Surprise Ratio
BIIB beat 36 of 43 last estimates.
84%
Next Report
Date of Next Report
Feb 04, 2027
Estimate for Q4 26 (Revenue/ EPS)
$2.61B
/$2.90
Implied change from Q3 26 (Revenue/ EPS)
-6.99%
/+10.69%
Implied change from Q4 25 (Revenue/ EPS)
+14.42%
/+45.73%
Biogen Inc. Common Stock earnings per share and revenue
On Oct 28, 2026, BIIB reported earnings of 2.62 USD per share (EPS) for Q3 26, beating the estimate of 2.03 USD, resulting in a 28.95% surprise. Revenue reached 2.80 billion, compared to an expected 2.69 billion, with a 4.39% difference. The market reacted with a -3.43% price change (close before vs. close after earnings).
Looking ahead to Q4 26, -- analysts forecast an EPS of 2.90 USD, with revenue projected to reach 2.61 billion USD, implying an increase of 10.69% EPS, and decrease of -6.99% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Royalty Pharma plc Class A Ordinary Shares
Report Date
Nov 04, 2026 For Q3 26
Estimate
$1.20
Actual
$1.21
Surprise
+0.39%
BioNTech SE - ADR
Report Date
Nov 03, 2026 For Q3 26
Estimate
$0.80
Actual
$1.81
Surprise
+126.53%
Rhythm Pharmaceuticals, Inc. Common Stock
Report Date
Nov 03, 2026 For Q3 26
Estimate
-$0.72
Actual
-$0.61
Surprise
+15.83%
Tarsus Pharmaceuticals, Inc. Common Stock
Report Date
Nov 03, 2026 For Q3 26
Estimate
-$2.78
Actual
-$0.78
Surprise
+72.00%
Viridian Therapeutics, Inc. Common Stock
Report Date
Nov 04, 2026 For Q3 26
Estimate
-$0.98
Actual
-$0.81
Surprise
+18.04%
Harmony Biosciences Holdings, Inc. Common Stock
Report Date
Nov 04, 2026 For Q3 26
Estimate
$1.15
Actual
$0.81
Surprise
-30.03%
uniQure N.V.
Report Date
Nov 04, 2026 For Q3 26
Estimate
-$0.94
Actual
-$0.88
Surprise
+6.39%
UroGen Pharma Ltd. Ordinary Shares
Report Date
Nov 04, 2026 For Q3 26
Estimate
$0.13
Actual
-$0.03
Surprise
-121.79%
Geron Corp
Report Date
Nov 04, 2026 For Q3 26
Estimate
$0.00
Actual
$0.00
Surprise
+100.00%
Nuvectis Pharma, Inc. Common Stock
Report Date
Nov 04, 2026 For Q3 26
Estimate
-$0.24
Actual
-$1.02
Surprise
-313.79%
FAQ
What were Biogen Inc. Common Stock's earnings and revenue for the latest quarter Q3 2026?
For Q3 2026, Biogen Inc. Common Stock reported EPS of $2.62, beating estimates by 28.95%, and revenue of $2.80B, 4.39% above expectations.
How did the market react to Biogen Inc. Common Stock's Q3 2026 earnings?
The stock price moved down -3.43%, changed from $252.73 before the earnings release to $244.05 the day after.
When is Biogen Inc. Common Stock expected to report next?
The next earning report is scheduled for Feb 04, 2027.
What are the forecasts for Biogen Inc. Common Stock's next earnings report?
Based on --
analysts, Biogen Inc. Common Stock is expected to report EPS of $2.90 and revenue of $2.61B for Q4 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.